{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:15:17Z","timestamp":1789143317325,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This study aims to explore the potential association between propranolol and cardiovascular adverse events (AEs) through real-world evidence. Reports from the FDA Adverse Event Reporting System (FAERS) database spanning from January 2014 to September 2024, identifying propranolol oral solution as the primary suspected (PS) drug, were analyzed. Disproportionality analysis employed four key metrics: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma-Poisson Shrinkage (MGPS) to identify positive signals of cardiovascular AEs potentially associated with propranolol oral solution. Among 7,518 AE reports where propranolol oral solution was the PS drug, 196 cardiovascular AEs were identified. Peripheral coldness (<jats:italic>n<\/jats:italic>\u2009=\u2009131, ROR 85.58, PRR 84.11), cyanosis (<jats:italic>n<\/jats:italic>\u2009=\u200924, ROR 15.91, PRR 15.87), and pallor (<jats:italic>n<\/jats:italic>\u2009=\u200912, ROR 3.79, PRR 3.79) were potentially associated with propranolol oral solution use. However, no positive signals were observed for other cardiovascular AEs, such as hypotension, bradycardia, or arrhythmias. Apart from peripheral vascular changes, our analysis did not detect positive signals for severe cardiovascular AEs, suggesting a favorable cardiovascular safety profile, though FAERS limitations such as underreporting warrant cautious interpretation. To ensure safety, standardized use and monitoring remain crucial.<\/jats:p>","DOI":"10.1038\/s41598-025-07577-3","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:34:13Z","timestamp":1751888053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular safety of propranolol oral solution in infantile hemangiomas: a disproportionality analysis based on the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Wenjia","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"7577_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze, C. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl. J. Med. 372, 735\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1404710 (2015).","journal-title":"N Engl. J. Med."},{"key":"7577_CR2","doi-asserted-by":"publisher","first-page":"e0138100","DOI":"10.1371\/journal.pone.0138100","volume":"10","author":"X Liu","year":"2015","unstructured":"Liu, X., Qu, X., Zheng, J. & Zhang, L. Effectiveness and safety of oral propranolol versus other treatments for infantile hemangiomas: a meta-analysis. PLoS One. 10, e0138100. https:\/\/doi.org\/10.1371\/journal.pone.0138100 (2015).","journal-title":"PLoS One"},{"key":"7577_CR3","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (2024)."},{"key":"7577_CR4","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1017\/S1047951123000847","volume":"33","author":"N Maliqari","year":"2023","unstructured":"Maliqari, N., Duka, E. & Kuneshka, L. Cardiac side effects of propranolol in infants treated for infantile haemangiomas. Cardiol. Young. 33, 2616\u20132620. https:\/\/doi.org\/10.1017\/S1047951123000847 (2023).","journal-title":"Cardiol. Young"},{"key":"7577_CR5","unstructured":"Shahrokhi, M. & Gupta, V. Propranolol. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557801\/ (Treasure Island (FL): StatPearls Publishing, 2025)."},{"key":"7577_CR6","doi-asserted-by":"publisher","first-page":"1542348","DOI":"10.3389\/fped.2025.1542348","volume":"13","author":"W Chen","year":"2025","unstructured":"Chen, W. et al. Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China. Front. Pediatr. 13, 1542348 (2025). https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11832506\/","journal-title":"Front. Pediatr."},{"key":"7577_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41598-024-84653-0","volume":"15","author":"Z Wu","year":"2025","unstructured":"Wu, Z. et al. Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China. Sci. Rep. 15, 459. https:\/\/doi.org\/10.1038\/s41598-024-84653-0 (2025).","journal-title":"Sci. Rep."},{"key":"7577_CR8","unstructured":"U.S. Food and Drug Administration. FDA\u2019s Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers (2024)."},{"key":"7577_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 18, 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"7577_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti, M., Fusaroli, M., Poluzzi, E., De Ponti, F. & Raschi, E. Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur. J. Prev. Cardiol. 28, 983\u2013989. https:\/\/doi.org\/10.1177\/2047487320915663 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"7577_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"7577_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"7577_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"7577_CR14","doi-asserted-by":"publisher","unstructured":"DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53, 177\u2013190. https:\/\/doi.org\/10.1080\/00031305.1999.10474456 (1999).","DOI":"10.1080\/00031305.1999.10474456"},{"key":"7577_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.011","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect. Disord. 346, 223\u2013229. https:\/\/doi.org\/10.1016\/j.jad.2023.11.011 (2024).","journal-title":"J. Affect. Disord"},{"key":"7577_CR16","doi-asserted-by":"publisher","first-page":"e20160353","DOI":"10.1542\/peds.2016-0353","volume":"138","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2016","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze, C. et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics 138, e20160353. https:\/\/doi.org\/10.1542\/peds.2016-0353 (2016).","journal-title":"Pediatrics"},{"key":"7577_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/pde.15623","volume":"41","author":"CY Huang","year":"2024","unstructured":"Huang, C. Y., Perman, M. J. & Yan, A. C. Regimen for accelerated propranolol initial dosing (RAPID). Pediatr. Dermatol. 41, 621\u2013627. https:\/\/doi.org\/10.1111\/pde.15623 (2024).","journal-title":"Pediatr. Dermatol."},{"key":"7577_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12519-019-00285-9","volume":"15","author":"H Yang","year":"2019","unstructured":"Yang, H. et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J. Pediatr. 15, 546\u2013558. https:\/\/doi.org\/10.1007\/s12519-019-00285-9 (2019).","journal-title":"World J. Pediatr."},{"key":"7577_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.21037\/atm.2019.10.47","volume":"7","author":"ZY Chen","year":"2019","unstructured":"Chen, Z. Y. et al. Progress in the treatment of infantile hemangioma. Ann. Transl Med. 7, 692. https:\/\/doi.org\/10.21037\/atm.2019.10.47 (2019).","journal-title":"Ann. Transl Med."},{"key":"7577_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2020.04.013","volume":"85","author":"KB Puttgen","year":"2021","unstructured":"Puttgen, K. B. et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J. Am. Acad. Dermatol. 85, 345\u2013352. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.013 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"7577_CR21","doi-asserted-by":"publisher","first-page":"1280948","DOI":"10.3389\/fphar.2024.1280948","volume":"15","author":"Y Zou","year":"2024","unstructured":"Zou, Y. et al. Historical and contemporary management of infantile hemangiomas: a single-center experience. Front. Pharmacol. 15, 1280948. https:\/\/doi.org\/10.3389\/fphar.2024.1280948 (2024).","journal-title":"Front. Pharmacol."},{"key":"7577_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.17219\/acem\/94136","volume":"28","author":"L Babiak-Choroszczak","year":"2019","unstructured":"Babiak-Choroszczak, L. et al. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. Adv. Clin. Exp. Med. 28, 375\u2013384. https:\/\/doi.org\/10.17219\/acem\/94136 (2019).","journal-title":"Adv. Clin. Exp. Med."},{"key":"7577_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1542\/peds.2012-1691","volume":"131","author":"BA Drolet","year":"2013","unstructured":"Drolet, B. A. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 131, 128\u2013140. https:\/\/doi.org\/10.1542\/peds.2012-1691 (2013).","journal-title":"Pediatrics"},{"key":"7577_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000450755","volume":"99","author":"P Salice","year":"2017","unstructured":"Salice, P. et al. Cardiovascular profile of propranolol after multiple dosing in infantile hemangioma. Pharmacology 99, 75\u201378. https:\/\/doi.org\/10.1159\/000450755 (2017).","journal-title":"Pharmacology"},{"key":"7577_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s13312-021-2286-3","volume":"58","author":"V Pandey","year":"2021","unstructured":"Pandey, V. et al. Adverse drug reactions following propranolol in infantile hemangioma. Indian Pediatr. 58, 753\u2013755. https:\/\/doi.org\/10.1007\/s13312-021-2286-3 (2021).","journal-title":"Indian Pediatr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07577-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07577-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07577-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:34:14Z","timestamp":1751888054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07577-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7577"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07577-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24253"}}